A.T.Y. Ko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
A.T.Y. Ko has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
B.K. Chung
2 shared publications- Chen Ting Tan
Department of Cardiology, Sarawak Heart Center, Kota Samarahan, Sarawak, Malaysia
2 shared publications E.Z. Chan
2 shared publicationsH.B. Chow
2 shared publicationsH.K. Khor
2 shared publications- Hwei Sung Ling
Universiti Malaysia Sarawak
2 shared publications
Latest Publications
- Open Access
- 29 December 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 393, 131469
Impact of total ischemic time (TIT) on 1-month clinical outcomes at a tertiary cardiology centre (TCC) with a limited primary percutaneous coronary intervention (LPPCI) service in the management of ST-elevation myocardial infarction (STEMI)
- 29 December 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 393, 131469
Open AccessImpact of total ischemic time (TIT) on 1-month clinical outcomes at a tertiary cardiology centre (TCC) with a limited primary percutaneous coronary intervention (LPPCI) service in the management of ST-elevation myocardial infarction (STEMI)
- Open Access
- 29 December 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 393, 131458
Echocardiographic improvement of left atrial booster pump and reservoir function observed in heart failure with improved ejection fraction and its prognostication
- 29 December 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 393, 131458
Open AccessEchocardiographic improvement of left atrial booster pump and reservoir function observed in heart failure with improved ejection fraction and its prognostication
- Open Access
Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma
Sarcomas are a heterogeneous group of mesenchymal neoplasms, many of which are associated with a high risk of metastasis and poor prognosis. Conventional chemotherapy and targeted therapies have varying effects across individuals and tumour subtypes. The current therapies frequently provide limited clinical benefit; hence, more effective treatments are urgently needed. Recent advances in immunotherapy, such as checkpoint inhibition or adoptive cell therapy (ACT), show potential in increasing efficacy by providing a more personalized treatment. Therapy with tumour-infiltrating lymphocytes (TILs) is an emerging field in immunotherapy. Here, we collected 190 sarcoma tumour specimens from patients without pre-operative adjuvant treatment in order to isolate TILs. We compared different methods of TIL expansion and optimized a protocol specifically for efficacy in culturing TILs from sarcoma. The expanded TIL populations were characterized by flow cytometry analysis using CD3, CD4, CD8, CD14, CD19 and CD56 markers. The TIL populations were non-specifically stimulated to establish TIL reactivity. Through an optimized expansion protocol, TILs were isolated and cultured from 54 of 92 primary sarcoma specimens. The isolated TILs varied in CD4+ and CD8+ T-cell compositions and retained their ability to release IFNγ upon stimulation. Our results suggest that certain sarcoma subtypes have the potential to yield a sufficient number of TILs for TIL therapy.
Open AccessInvestigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma
Sarcomas are a heterogeneous group of mesenchymal neoplasms, many of which are associated with a high risk of metastasis and poor prognosis. Conventional chemotherapy and targeted therapies have varying effects across individuals and tumour subtypes. The current therapies frequently provide limited clinical benefit; hence, more effective treatments are urgently needed. Recent advances in immunotherapy, such as checkpoint inhibition or adoptive cell therapy (ACT), show potential in increasing efficacy by providing a more personalized treatment. Therapy with tumour-infiltrating lymphocytes (TILs) is an emerging field in immunotherapy. Here, we collected 190 sarcoma tumour specimens from patients without pre-operative adjuvant treatment in order to isolate TILs. We compared different methods of TIL expansion and optimized a protocol specifically for efficacy in culturing TILs from sarcoma. The expanded TIL populations were characterized by flow cytometry analysis using CD3, CD4, CD8, CD14, CD19 and CD56 markers. The TIL populations were non-specifically stimulated to establish TIL reactivity. Through an optimized expansion protocol, TILs were isolated and cultured from 54 of 92 primary sarcoma specimens. The isolated TILs varied in CD4+ and CD8+ T-cell compositions and retained their ability to release IFNγ upon stimulation. Our results suggest that certain sarcoma subtypes have the potential to yield a sufficient number of TILs for TIL therapy.
- 1 February 2016
- Published by Elsevier in Cancer Letters
- Vol. 371 (2) , 251-261
The synthetic β-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway
- 1 February 2016
- Published by Elsevier in Cancer Letters
- Vol. 371 (2) , 251-261
The synthetic β-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway